Automate Your Wheel Strategy on JNJ
With Tiblio's Option Bot, you can configure your own wheel strategy including JNJ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JNJ
- Rev/Share 37.1342
- Book/Share 32.4693
- PB 4.73
- Debt/Equity 0.669
- CurrentRatio 1.2574
- ROIC 0.1201
- MktCap 369524230600.0
- FreeCF/Share 7.7211
- PFCF 19.8947
- PE 16.9397
- Debt/Assets 0.2698
- DivYield 0.0327
- ROE 0.2995
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | JNJ | Leerink Partners | Outperform | Market Perform | -- | $153 | May 13, 2025 |
| Resumed | JNJ | BofA Securities | -- | Neutral | -- | $166 | Dec. 10, 2024 |
News
Johnson & Johnson: Relative Stability In A Wild 2025 Stock Market
Published: May 30, 2025 by: Seeking Alpha
Sentiment: Positive
Johnson & Johnson remains undervalued with strong profitability and reasonable valuation metrics, but growth prospects are modest and uncertain. Profitability is robust, with an A+ grade, high margins, and nearly 30% return on equity, supporting the company's structural quality. Key risks include regulatory challenges, legal liabilities from talc lawsuits, and potential price controls on major drugs like Darzalex Faspro.
Read More
Johnson & Johnson (JNJ) Presents at the Bernstein's 41st Annual Strategic Decisions Conference (Transcript)
Published: May 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Johnson & Johnson (NYSE:JNJ ) Bernstein's 41st Annual Strategic Decisions Conference Call May 28, 2025 9:00 AM ET Company Participants Joaquin Duato - Chairman and Chief Executive Officer Joseph Wolk - Executive Vice President, Chief Financial Officer Conference Call Participants Lee Hambright - Bernstein Lee Hambright All right, thank you, everybody. Thanks, guys.
Read More
No Rolex For Me - I'm Buying Dividends That Pay For Life
Published: May 26, 2025 by: Seeking Alpha
Sentiment: Positive
I love luxury watches, but buying more to "earn" access to rarer models made me realize how easy it is to waste capital chasing ego-driven goals. Unlike watches, dividend growth stocks offer reliable long-term returns. A $10K McDonald's investment in 2004 would've yielded over $22K in dividends alone. History shows that strong-yielding dividend stocks, especially those in the second quintile, have consistently outperformed the market with lower risk.
Read More
FDA Panel Reiterates the Cancer Risks of Talc
Published: May 23, 2025 by: Business Wire
Sentiment: Neutral
WASHINGTON--(BUSINESS WIRE)--A panel of medical experts convened by the U.S. Food & Drug Administration urged the agency to study and adopt new standards to prohibit the use of talc in consumer products such as gum, candy, rice and pharmaceuticals. Many of the experts cited the more than 30 years of studies showing an association between talc use and ovarian cancer, which led Johnson & Johnson (NYSE:JNJ) to remove the company's iconic body powders from the market in recent years. “It's.
Read More
Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Neutral
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $152.51, denoting a -0.44% change from the preceding trading day.
Read More
JNJ Down 6% in 3 Months: How to Play the Stock Amid Various Challenges
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Negative
J&J's JNJ stock has declined 6.4% in the past three months. J&J faces several challenges, including slowing sales in the MedTech segment, loss of exclusivity of its blockbuster drug, Stelara, and uncertainty around the talc lawsuits, among others.
Read More
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma
Published: May 20, 2025 by: PRNewsWire
Sentiment: Neutral
ODAC recommendation based on the positive progression-free survival and clinical benefit in the Phase 3 AQUILA study If approved, DARZALEX FASPRO® would be the first treatment to potentially delay or prevent progression to multiple myeloma RARITAN, N.J. , May 20, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted (6-2) in favor of the benefit-risk profile of single-agent DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) for the treatment of adult patients with high-risk smoldering multiple myeloma (HR-SMM).
Read More
Johnson & Johnson (JNJ) RBC Capital Markets Global Healthcare Conference
Published: May 20, 2025 by: Seeking Alpha
Sentiment: Neutral
Johnson & Johnson (NYSE:JNJ ) RBC Capital Markets Global Healthcare Conference May 20, 2025 1:35 PM ET Corporate Participants Joe Wolk - EVP, Chief Financial Officer Conference Call Participants Shagun Singh - RBC Capital Markets Shagun Singh Hello everyone, I am Shagun Singh, Senior Research Analyst at RBC, and I'm very happy to host the next session with Johnson & Johnson. Joining us from the company is Joe Wolk, Chief Financial Officer of the company.
Read More
Dean Omar Branham Shirley Recognized Twice Among ALM's 2024 Top 100 Verdicts
Published: May 20, 2025 by: Business Wire
Sentiment: Neutral
DALLAS--(BUSINESS WIRE)--National plaintiffs firm Dean Omar Branham Shirley, LLP, has been recognized by ALM and Law.com for securing two of the largest jury verdicts of 2024. Both cases involved claims against pharmaceutical giant Johnson & Johnson (NYSE:JNJ) over its talc-based Baby Powder, which exposed users to asbestos, a known carcinogen. The 29th-ranked case on the ALM list was a $260 million verdict in Oregon on behalf of Kyung Lee, a 49-year-old mother of three who was diagnosed wi.
Read More
Moody's U.S. Debt Downgrade: Stocks Poised To Benefit
Published: May 19, 2025 by: Seeking Alpha
Sentiment: Positive
Corporations play a vital and often benevolent role in capitalist societies, supporting economic growth and innovation with more conservative balance sheets than their governments. Microsoft, Apple and Johnson & Johnson hold Moody's highest credit rating of Aaa, reflecting exceptional financial strength and stability. Alphabet and Berkshire Hathaway are rated Aa2 by Moody's, indicating very high credit quality, just below the top tier.
Read More
The Only 5 ETFs You Need to Build Wealth for Retirement
Published: May 19, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Dividend stocks are a foundational building block for creating a retirement portfolio, offering a reliable income stream and potential for capital appreciation.
Read More
Statement On $147M Verdict for AMDR Member Innovative Health Against Johnson & Johnson's Biosense Webster Medical Technology Unit
Published: May 18, 2025 by: Business Wire
Sentiment: Neutral
WASHINGTON & BERLIN--(BUSINESS WIRE)--Association of Medical Device Reprocessors issued the following statement: Friday's unanimous verdict by a federal jury in Santa Ana, California for Innovative Health against Johnson & Johnson (NYSE: JNJ) is a victory for America's hospitals, providers, patients, and the environment. The jury found that Biosense Webster violated federal and state antitrust laws by withholding clinical support to hospitals using Innovative Health's FDA regulated, reproce.
Read More
Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
If You Invested $25,000 In Johnson & Johnson (JNJ) 20 Years Ago, This Is How Much Cash From Dividends You Would Have Today
Published: May 15, 2025 by: 24/7 Wall Street
Sentiment: Positive
Companies with strong products, good management, solid earnings and growth trends, and a history of annual dividend increases are often popular buy and hold stocks to take advantage of dividend compounding.
Read More
Why Is Johnson & Johnson (JNJ) Down 4.9% Since Last Earnings Report?
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Negative
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
Read More
Johnson & Johnson (JNJ) BofA Securities 2025 Healthcare Conference Transcript
Published: May 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Johnson & Johnson (NYSE:JNJ ) BofA Securities 2025 Healthcare Conference May 13, 2025 1:40 PM ET Company Participants John Reed - Executive Vice President, Innovative Medicine, R&D Conference Call Participants Tim Anderson - Bank of America Tim Anderson I think we're live. Thank you for joining us.
Read More
Johnson & Johnson: For Those Who Want Some Immunity Against Tariff Changes
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Negative
The U.S. and China have agreed to reduce tariffs temporarily for 90 days. I expect continued market volatility in the negotiation process. Johnson & Johnson could offer some immunity due to the specific breakdown of the trade between these two countries and JNJ's relatively minor exposure to China.
Read More
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach.
Read More
Pharma Stocks Hit by Trump's Vow to Cut US Prescription Drug Costs
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Negative
The price cuts would see that U.S. consumers pay the same amount as the nation that pays the lowest price for that drug.
Read More
J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Data from a late-stage study shows that treatment with JNJ's icotrokinra helps achieve significant skin clearance in hard-to-treat scalp and genital psoriasis.
Read More
Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis
Published: May 09, 2025 by: PRNewsWire
Sentiment: Neutral
66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin at Week 16 Icotrokinra continues to demonstrate a standout combination of significant skin clearance (IGA 0/1) and a favorable safety profile in a once daily pill SPRING HOUSE, Pa. , May 9, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ICONIC-TOTALa study investigating icotrokinra (JNJ-2113), the first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor.
Read More
4 High-Yielding Dogs of the Dow Are Crushing the Major Indices
Published: May 09, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors love dividend stocks, especially high-yield ones, because they offer significant income streams and have substantial total return potential.
Read More
Jury Orders Johnson & Johnson to Pay $3 Million in Mesothelioma Death of New Orleans Woman
Published: May 08, 2025 by: Business Wire
Sentiment: Neutral
NEW ORLEANS--(BUSINESS WIRE)--A jury has awarded $3 million to the family of Jeanine Henderson, a 72-year-old mother from New Orleans who died from mesothelioma, a rare and incurable cancer caused by asbestos exposure, after a lifetime of using Johnson & Johnson's Baby Powder. After a two-month trial, attorneys from Dean Omar Branham Shirley successfully proved that Ms. Henderson's daily use of the talc-based powder was directly linked to her illness. The legal team also presented clear evi.
Read More
Dividend Hikes Offer Optimism Amid Tariff Turmoil
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Positive
Stocks have rebounded sharply off their early-April lows, but macro risks persist. Dividend stocks have largely outperformed so far this year. We profile a pair of blue chips that recently announced dividend hikes, which has turned out to be a broader Q2 theme.
Read More
3 Stable Stocks to Buy When the Price is Right
Published: May 06, 2025 by: Morningstar
Sentiment: Positive
There's no such thing as a safe stock, but these low-volatility names stand up relatively well in shaky markets.
Read More
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Read More
JNJ vs. ABBV: Which Pharma Powerhouse Has Better Growth Prospects?
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Both JNJ and ABBV expect their sales and profits to improve in 2025.
Read More
FDA Approves Johnson & Johnson's IMAAVYTM (nipocalimab-aahu) a New Treatment for Myasthenia Gravis (MG), Offering Hope for Families
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older. First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older.
Read More
US FDA approves J&J's immune disorder drug
Published: April 30, 2025 by: Reuters
Sentiment: Positive
The U.S. Food and Drug Administration has approved Johnson & Johnson's drug to treat patients aged 12 years and older with an immune-mediated disorder, the drugmaker said on Wednesday.
Read More
About Johnson & Johnson (JNJ)
- IPO Date 1943-01-02
- Website https://www.jnj.com
- Industry Drug Manufacturers - General
- CEO Mr. Joaquin Duato
- Employees 138100